DYV700 / Dyve Biosci - LARVOL DELTA

Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS) (clinicaltrials.gov) - P2 | N=284 | Completed | Sponsor: Dyve Biosciences, Inc. | Recruiting ➔ Completed | Trial primary completion date: Feb 2021 ➔ May 2021

Trial completion • Trial primary completion date • Gout • Inflammatory Arthritis • Pain • Rheumatology

[VIRTUAL] Dyve Biosciences (BIO 2021) - "Dyve is a clinical stage biotech company with its lead asset, DYV700, currently completing a 20- center, 100-patient, Phase 2 clinical study for the treatment of acute gout...It combines the fast onset of action of an injection with the extended duration and bioavailability of an oral pill – creating ideal PK/PD parameters and an optimal drug profile. Dyve has a robust internal pipeline of novel drugs and a research collaboration in place with a Top 10 Pharmaceutical Company on a separate set of target NCEs."

Gout • Inflammatory Arthritis • Rheumatology

Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS) (clinicaltrials.gov) - P2; N=300; Recruiting; Sponsor: Dyve Biosciences, Inc.; Enrolling by invitation ➔ Recruiting

Clinical • Enrollment status

Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS) (clinicaltrials.gov) - P2; N=300; Enrolling by invitation; Sponsor: Dyve Biosciences, Inc.; Not yet recruiting ➔ Enrolling by invitation

Clinical • Enrollment open